Axon Enterprise INC Stock
Price
Target price
€360.10
€360.10
-1.640%
-6.0
-1.640%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Axon Enterprise INC Stock
A loss of -1.640% shows a downward development for Axon Enterprise INC.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Axon Enterprise INC stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Axon Enterprise INC in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
G***** c******* t* c**********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Axon Enterprise INC vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Axon Enterprise INC | -1.640% | 0.356% | -32.578% | -43.311% | -25.589% | 111.741% | 118.176% |
| Kratos Defense & Security Solutions | 0.430% | -4.471% | -24.293% | 138.760% | 12.889% | 607.639% | 175.051% |
| Moog Inc. | 0.660% | -0.587% | 15.614% | 46.566% | 27.830% | 188.298% | 307.519% |
| Heico Corp. | 1.290% | -1.128% | -10.533% | 21.339% | -3.032% | 66.748% | 150.368% |
Comments
News
Axon Neuroscience's Immunotherapy Selected for a Landmark Combination-Therapy Alzheimer’s Clinical Trial in US, Supported by a USD 151 Million Grant
Axon Neuroscience's active tau immunotherapy AADvac1 has been selected as the first tau-targeted therapy to enter a groundbreaking U.S. Alzheimer's disease phase 2 clinical trial (supported
Why Axon Enterprise Stock Plunged Week
Shares of Axon Enterprise (NASDAQ: AXON), the maker of TASER electrical weapons and body cameras, were taking a dive this week, even though there was no major company-specific news out on it.
The Motley Fool Interviews Axon Enterprise President Josh Isner
Law enforcement technology company Axon Enterprise has produced big returns for investors. Motley Fool analyst Jason Moser recently talked with Axon President Josh Isner about the recent quarter